KMT2D and astrocytoma (excluding glioblastoma): Overall, a higher prevalence of CR mutations in the astrocytoma, IDH-mut group was seen (15.3% vs. 8.9% in glioblastoma, IDH-WT, q < .0001), and the difference was primarily found in components of SWI/SNF complexes (9.8% vs. 3.1%, q < .0001) and one histone methyltransferase (HM), including ARID1A (3.64% vs 1.27%, q < .0001), ARID2 (2.37%, vs 0.84%, q = .014), SMARCA4 (3.30% vs 0.49%, q < .0001), and KMT2D (2.12% vs 0.70%, q = .046) in astrocytoma, IDH-mut and glioblastoma, IDH-WT, respectively.